Innovative Molecules

Executive Summary

Innovative Molecules, a German biotech based in Munich, is advancing a novel class of small molecule therapies for herpes simplex virus (HSV) infections. Founded in 2018, the company's lead candidate, IM-250 (adibelivir), is an orally available helicase-primase inhibitor designed to overcome limitations of current nucleoside analog treatments, such as acyclovir resistance and latent virus reactivation. IM-250 has shown promising preclinical efficacy in reducing viral shedding and latency, and is currently in Phase 2 clinical trials for recurrent genital herpes. The company is also exploring IM-250's potential in other HSV-mediated diseases, including ocular herpes and neonatal herpes. With a strong IP portfolio and a team of clinical experts, Innovative Molecules aims to provide a transformative therapy for the millions of patients suffering from HSV infections worldwide.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 topline data for IM-250 in recurrent genital herpes65% success
• Q4 2026Initiation of Phase 2b/3 trial for IM-25050% success
• Q4 2026Strategic partnership or licensing deal for ex-Europe rights40% success